Cancer and diabetes therapies potential uses for deidentified

Cancer and diabetes therapies
A leader in developing innovative therapeutics in the areas of oncology and endocrinology, this major biopharmaceutical organization assists specialty pharmacies and other healthcare providers by extracting patient-level data related to drug dispensing and clinical management of specific patient populations. The data they use for secondary purposes are obtained from specialty pharmacies. The deidentified data include information on patients, payers, claims, diagnoses, prescription and dispensary data. Using a data aggregator partnership, they regularly perform risk-based de-identification on their data through a secure process. They then use the de-identified data to assist providers in improving clinical care for their patients and for their business operations.